Crossmark

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

Crossref DOI link: https://doi.org/10.1038/s41375-018-0346-z

Published Online: 2019-01-11

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jawhar, Mohamad

Döhner, Konstanze

Kreil, Sebastian

Schwaab, Juliana

Shoumariyeh, Khalid

Meggendorfer, Manja

Span, Lambert L. F.

Fuhrmann, Stephan

Naumann, Nicole

Horny, Hans-Peter

Sotlar, Karl

Kubuschok, Boris

von Bubnoff, Nikolas

Spiekermann, Karsten

Heuser, Michael

Metzgeroth, Georgia

Fabarius, Alice

Klein, Stefan

Hofmann, Wolf-Karsten

Kluin-Nelemans, Hanneke C.

Haferlach, Torsten

Döhner, Hartmut

Cross, Nicholas C. P. https://orcid.org/0000-0001-5481-2555
Sperr, Wolfgang R.

Valent, Peter

Reiter, Andreas
License Information

Text and Data Mining valid from 2019-01-11
More Information

Article History

Received: 11 September 2018

Revised: 2 November 2018

Accepted: 6 November 2018

First Online: 11 January 2019

Conflict of interest

: H-PH, K Sotlar, PV, and AR served as consultants in a global phase-II-study examining the effects of midostaurin in advanced systemic mastocytosis. H-PH, K Sotlar, K Shoumariyeh, PV, NCPC, and AR received honoraria and/or travel support from Novartis Pharmaceuticals. MJ and JS received travel support from Novartis Pharmaceuticals. TH has equity ownership of the MLL Munich Leukemia Laboratory. MM is employed by the MLL Munich Leukemia Laboratory. The remaining authors declare that they have no conflict of interest.